CAR+ T-cell lymphoma linked to cilta-cel therapy in myeloma
1. This study describes two cases of malignant monoclonal T-cell lymphoproliferation following ciltacabtagene autoleucel (cilta-cel) Chimeric Antigen Receptor T-cell (CAR ...
Tag: hematology
Beti-cel gene therapy achieves high rates of transfusion independence in severe β-thalassemia
1. 89% of patients achieved transfusion independence with beti-cel gene therapy. 2. There were no serious adverse events or treatment-related ...
Intra-arterial tenecteplase has limited use after successful endovascular recanalisation of acute posterior circulation arterial occlusion
1. In patients with acute ischemic stroke due to acute intracranial occlusions of the posterior circulation, the use of intra-arterial ...
2 Minute Medicine Rewind January 13, 2025
Association of varicose veins with the risk of heart failure: A nationwide cohort study 1. Patients with varicose veins had ...
Incyte: Monjuvi improves survival in patients with relapsed or refractory follicular lymphoma
The addition of Monjuvi to standard-of-care therapy reduced the risk of disease progression, relapse, or death in patients with relapsed/refractory ...
Sanofi’s Sarclisa approved as first-line for transplant-ineligible multiple myeloma patients
Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ineligible ...
Pomalidomide effective in reducing epistaxis in hereditary hemorrhagic telangiectasia
1. Among patients with hereditary hemorrhagic telangiectasia (HHT), pomalidomide significantly reduced the severity of epistaxis and improved quality of life. ...
Fidanacogene elaparovovec may reduce bleeding in men with hemophilia B
1. In this randomized controlled trial, fidanacogene elaparovovec therapy significantly reduced the mean annualized rate of bleeding in adult men ...
Axatilimab reduces symptoms in patients with graft versus host disease
1. In this randomized controlled trial, axatilimab effectively managed symptoms in patients with recurrent or refractory graft versus host disease ...
Anemia is a common side effect of antiretroviral therapy for HIV
1. Patients with HIV treated with antiretroviral therapy (ART) have a 31.5% chance of being anemic with many significantly positively ...
